TARO vs. BPMC, OGN, IONS, BBIO, CYTK, APLS, MDGL, ALPN, NUVL, and ALKS
Should you be buying Taro Pharmaceutical Industries stock or one of its competitors? The main competitors of Taro Pharmaceutical Industries include Blueprint Medicines (BPMC), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), and Alkermes (ALKS). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines (NASDAQ:BPMC) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
In the previous week, Blueprint Medicines had 2 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 5 mentions for Blueprint Medicines and 3 mentions for Taro Pharmaceutical Industries. Taro Pharmaceutical Industries' average media sentiment score of 0.62 beat Blueprint Medicines' score of -0.10 indicating that Blueprint Medicines is being referred to more favorably in the media.
Blueprint Medicines has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Blueprint Medicines received 228 more outperform votes than Taro Pharmaceutical Industries when rated by MarketBeat users. Likewise, 67.84% of users gave Blueprint Medicines an outperform vote while only 62.05% of users gave Taro Pharmaceutical Industries an outperform vote.
Taro Pharmaceutical Industries has a net margin of 8.56% compared to Taro Pharmaceutical Industries' net margin of -102.15%. Blueprint Medicines' return on equity of 3.75% beat Taro Pharmaceutical Industries' return on equity.
Blueprint Medicines currently has a consensus price target of $103.94, indicating a potential downside of 1.54%. Taro Pharmaceutical Industries has a consensus price target of $43.00, indicating a potential upside of 0.42%. Given Blueprint Medicines' higher probable upside, analysts clearly believe Taro Pharmaceutical Industries is more favorable than Blueprint Medicines.
Taro Pharmaceutical Industries has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Taro Pharmaceutical Industries beats Blueprint Medicines on 10 of the 19 factors compared between the two stocks.
Get Taro Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taro Pharmaceutical Industries Competitors List
Related Companies and Tools
